A comparative study of cefozopran for bacterial pneumonia

Hiroyuki Kobayashi, Shin Kawai, Sokichi Onodera, Hitoshi Nakano, Tadakatsu Tsuji, Junichi Maruyama, Tetsuo Shimizu, Nobuhiro Sasaki, Yuka Fujita, Akira Saitoa, Akira Saitoa, Yohmei Hiraga, Mitsuhide Omichi, Kazuo Takebe, Mitsuo Masuda, Seiichi Murakami, Masakatsu Matsukawa, Hisashi Nakahata, Ken Osonoi, Miyoko SaitoMasashi Tamura, Kazuki Konishi, Kazuo Obara, Yoji Aoyama, Kazushige Sugawara, Kazuyasu Abe, Osamu Katagiri, Taiji Yoshida, Yuko Yasuda, Yasuyuki Suzuki, Masao Sato, Tamotsu Takishima, Yasuo Tanno, Masakichi Motomiya, Akira Watanabe, Yutaka Tokue, Shigeo Takizawa, Mikae Nakamura, Masaaki Arakawa, Koichi Wada, Fumihide Iwata, Shigeyuki Hoshino, Osamu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Hajime Takeda, Kaoru Shimada, Shinichi Oka, Yasuyuki Sano, Yasuko Tanaka, Osamu Sakai, Kohya Shiba, Kazuhisa Okada, Akira Tsuruoka, Junko Sanjo, Hiroichi Tanimoto, Hideo Ikemoto, Kazuo Obara, Katsumi Komatsuzaki, Osamu Tanabe, Hideo Ikemoto, Masaru Koyama, Koichiro Nakata, Koji Narui, Izumi Hayashi, Jingoro Shimada, Seiji Hori, Takao Okubo, Hirotada Ikeda, Shoichiro Irimajiri, Seiji Mita, Atsuhiko Sato, Kingo Chida, Masahiko Okano, Jinichiro Akiyama, Masami Taniguchi, Hirokazu Okano, Masaaki Ida, Toshihiko Takeuchi, Yasuo Yamada, Toshinobu Yamamoto, Hidekazu Hanaki, Tomonori Tashiro, Shinji Takeyama, Yoshimitsu Hayashi, Tsuyoshi Itoh, Kazuhide Yamamoto, Toshiyuki Yamamoto, Kanzo Suzuki, Toru Matsuura, Takateru Izumi, Naoki Fujimura, Hiroyuki Imai, Kohei Hamamoto, Keiji Hashimoto, Hitoshi Asamoto, Yoshiyuki Sasaki, Tateo Tsutsumi, Yasushi Takeda, Yoshihiro Ueda, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Fumio Miki, Tetsuto Murata, Rinzo Soejima, Yoshihito Niki, Masaru Sumi, Osamu Moriya, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Michiro Yamakido, Kenji Hasegawa, Isao Murakami, Yoshiro Sawae, Kaoru Okada, Koji Takaki, Kiyoshi Ninomiya, Yukio Kumagaya, Kotaro Oizumi, Yoichiro Ichikawa, Naoto Tokunaga, Eiichi Higuchi, Kazuma Fujino, Ken Araki, Yoshiyuki Mitsutake, Toshihiro Higashi, Kozo Ishii, Hiroshi Maruoka, Shoko Tanoue, Masashi Kawahara, Masazumi Saisho, Hironari Shigematsu, Shinzo Kawaguchi, Fumio Tanaka, Hiroaki Furuno, Takaoki Otsuka, Kohei Hara, Shigeru Kohno, Hironobu Koga, Masato Yatsugi, Kenji Kawano, Tadashi Nakano, Kazuo Sasayama, Naomi Ito, Osamu Sakito, Kazuhiro Okuno, Kiyoyasu Fukushima, Takeshi Ishizaki, Koichi Watanabe, Toru Ishino, Yuichi Inoue, Takakazu Otsubo, Sadahiro Asai, Naofumi Suyama, Hideo Mashimoto, Keizo Matsumoto, Takeshi Nagatake, Atsushi Takahashi, Yoshihiko Ikeda, Toshihiro Morito, Hiroyuki Yoshimine, Hiroshi Tanaka, Naoto Rikitomi, Tasuku Sakamoto, Mikio Taguchi, Hidehiko Hirose, Masashi Yamamoto, Shigeru Matsukura, Yasumasa Doutsu, Junichi Ashitani, Masaru Nasu, Tohru Yamazaki, Yoichiro Goto, Jun Goto, Kazuo Kitagawa, Saburo Urakami, Hiroshi Nagaoka, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Nobuchika Kusano, Daishiro Kitagawa, Mamoru Miyagi, Tominori Oyakawa, Izuru Gakiya, Nobuya Ogawa, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A comparative study has been conducted to determine the clinical efficacy, safety and utility of a new injectable cephem antibiotic cefozopran (CZOP) versus a control drug, ceftazidime (CAZ), for bacterial pneumonia. CZOP and CAZ were administered, in principle, by intravenous drip infusion at a dose of 1.0g (potency), twice daily for 14days, and the following results were obtained: 1. The efficacy rates for the total number of cases evaluated were 90.5% (95/105) in the CZOP group and 96.0% (97/101) in the CAZ group. 2. Bacteriological eradication rates were 94.3% (50/53) in the CZOP group and 97.6% (41/42) in the CAZ group. 3. Adverse reaction rates were 6.2% (7/113) in the CZOP group and 3.4% (4/117) in the CAZ group. Abnormal laboratory finding rates were 27.0% (30/111) in the CZOP group and 31.6% (37/ 117) in the CAZ group. 4. Usefulness rates were 87.6% (92/105) in the CZOP group and 91.2% (93/102) in the CAZ group. These results indicate that CZOP is useful for the treatment of bacterial pneumonia.

Original languageEnglish
Pages (from-to)963-988
Number of pages26
JournalCHEMOTHERAPY
Volume41
Issue number9
DOIs
Publication statusPublished - Jan 1 1993

Keywords

  • bacterial pneumonia
  • cefozopran, ceftazidime
  • comparative study

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'A comparative study of cefozopran for bacterial pneumonia'. Together they form a unique fingerprint.

  • Cite this

    Kobayashi, H., Kawai, S., Onodera, S., Nakano, H., Tsuji, T., Maruyama, J., Shimizu, T., Sasaki, N., Fujita, Y., Saitoa, A., Saitoa, A., Hiraga, Y., Omichi, M., Takebe, K., Masuda, M., Murakami, S., Matsukawa, M., Nakahata, H., Osonoi, K., ... Sugawara, K. (1993). A comparative study of cefozopran for bacterial pneumonia. CHEMOTHERAPY, 41(9), 963-988. https://doi.org/10.11250/chemotherapy1953.41.963